Albumin is a multifunctional transport protein that binds a wide variety ofendogenous substances and drugs. Insulins with affinity for albumin were engineered by acylation of the e-amino group of LysB29 with saturated fatty acids containing 10-16 carbon atoms. The association constants for binding of the fatty acid acylated insulins to human albumin are in the order of 104-105 M-1. The binding apparently involves both non-polar and ionic interactions with the protein. The acylated insulins bind at the long-chain fatty acid binding sites, but the binding affinity is lower than that of the free fatty acids and depends to a relatively small degree on the number of carbon atoms in the fatty acid chain. Differences in affinity of the acylated insulins for albumin are reflected in the relative timing of the blood-glucose-lowering effect after subcutaneous injection into rabbits. The acylated insulins provide a breakthrough in the search for soluble, prolonged-action insulin preparations for basal delivery of the hormone to the diabetic patient. We conclude that the biochemical concept of albumin binding can be applied to protract the effect ofinsulin, and suggest that derivatization with albuminbinding ligands could be generally applicable to prolong the action profile of peptide drugs.
INTRODUCTION
The therapeutic applicability of a biologically active peptide depends on the possibility of delivering it at its site of action with a suitable time-profile. Peptide and protein drug delivery is associated with several problems [1] . For example, peptides must in general be administered by injection because they are susceptible to enzymic breakdown and penetrate poorly through mucosal membranes. Furthermore, most peptides have a short half-life within the circulation and must be gradually released into the bloodstream to have a sustained effect. Advanced controlled-delivery systems for peptides, such as pumps, liposomes and microspheres, have not proved successful [2] .
Insulin is a peptide hormone that has been in clinical use for decades. To meet the requirement for a constant basal supply of the hormone, diabetic patients receive daily subcutaneous injec- R denotes the fatty acid attached by an amide bond to the e-amino group of LySB29. In the present study we have prepared derivatives of des-(B30) human insulin (X is deleted) in which R has from 10 to 16 carbon atoms, and analogues of human insulin (X is Thr) in which R has 10 or 14 carbon atoms.
tions of long-acting insulin suspensions [3] . In recent years, much effort has been devoted to the development of soluble, longacting insulin analogues with a more reproducible and a more prolonged effect than the insulin suspensions [4] [5] [6] , but no analogues have shown improved clinical results.
Albumin is a multifunctional transport protein that binds reversibly a wide variety of endogenous substances and drugs [7] [8] [9] [10] . Owing to the restricted passage of albumin-drug complexes across membranes, the pharmacokinetic parameters of many drugs can be altered by modification of their affinity for albumin [1 1,12] . To test whether albumin binding can be applied to protract the effect of peptide drugs, we have engineered insulin derivatives with affinity for albumin by acylation of the hormone with fatty acids (Figure 1 ). In the present study we investigate the interaction between the fatty acid acylated insulins and human serum albumin (HSA), using albumin immobilized on agarose. Differences in affinity of acylated insulins for albumin are correlated to the relative degree of protraction of the insulins in rabbits. The suitability of using albumin binding to protract insulin action is discussed.
EXPERIMENTAL Materials
Fatty acid-free (< 0.005 %) and globulin-free HSA purchased from Sigma were used throughout this study. Fatty acids of analytical grade were from Fluka AG (Switzerland) or Aldrich (Germany). Divinylsulphone-activated Sepharose 6B (Mini-Leak Low) was obtained from Kem-En-Tec A/S (Copenhagen, Denmark). Insulin Protaphane (NPH-insulin) and human insulin were supplied by Novo Nordisk A/S (Denmark). Des-(B30) human insulin was prepared as previously described [13] . [9,10-3H] Myristic acid (33.5 Ci/mmol) was supplied as an ethanolic 1 solution (1 mCi/ml) from DuPont NEN. All other chemicals used were of reagent grade or better.
Protein concentrations were determined by UV absorbance, taking molar absorption coefficients of e279 35 .7 x 10' M--cm-'
for HSA [7] and 6276 6.2 x 10' M-l cm-' for the insulins.
Preparation of fatty acid acylated Insulins
Human insulin and des-(B30) human insulin were treated with di-t-butyldicarbonate in DMSO/triethylamine (20: 1, v/v), and the GlyAl, PheBI di-Boc (where Boc represents t-butyloxycarbonyl) insulins were separated from the isomers by reversedphase HPLC. The hydroxysuccinimide esters of fatty acids were prepared from fatty acids and N-hydroxysuccinimide by using dicyclohexylcarbodiimide in dimethylformamide for ester formation, and ethanol for recrystallization of the products. The Camino group of LysB29 was selectively acylated by treatment of GlyAl, PheBI di-Boc insulin with the fatty acid hydroxysuccinimide esters in dimethylformamide/DMSO (1:7, v/v) at 15°C, using 20 equivalents of a tertiary amine such as 4- methylmorpholine. The protecting groups were removed with trifluoroacetic acid and the LysB29-acylated insulins were purified by reversed-phase HPLC. The identity of the fatty acid acylated insulins was confirmed by mass spectrometry, determining the molecular mass of the insulin derivative, of the B-chain after treatment with dithiothreitol, and of the B-chain fragment containing LysB29 obtained by treatment with Staphylococcus aureus protease.
Mono l25I-(TyrAl4)-labelled insulins were prepared as previously described [14] .
Immobilization of HSA
HSA was coupled to the activated agarose matrix (Mini-Leak Low) according to the guidelines of the manufacturer. For each gram of gel was added 2 ml of 5 % (w/v) HSA and 2 ml of 30 % (w/v) PEG 20000 in 0.3 M NaHCO3, pH 8.6. The suspension was gently agitated overnight at 23 'C. Excess active groups were blocked by treatment with 30 mM ethanolamine at pH 9.0 for 5 h at 23 'C. The molar content of HSA in the gel was 0.4-0.6 nmol per mg suction-dried gel as determined by titration with HSA in solution as described below. At pH 8.6, amino groups and thiol groups can be coupled to the activated matrix, whereas hydroxyl groups react at pH > 10 [15] . Because HSA contains 59 lysine residues and a single free cysteine [7] , the coupling is expected to involve primarily c-amino groups of lysine residues.
Equilibration of ligands with immobilized HSA Immobilized HSA was washed with 2-3 volumes of 0.1 M Tris, pH 7.4, on a suction filter and drained until cracks were seen in the gel. A portion of the gel was weighed out and suspended in 0.1 M Tris, pH 7.4, containing 0.025 % (v/v) Triton X-100 (Tris/TX-100). The concentration of immobilized HSA in the suspension was less than 40 mg/ml. The exclusion volume provided by the Mini-Leak matrix (less than 4% of the total volume) is considered to be insignificant. Portions of the suspension were pipetted into vials during stirring and combined with the radiolabelled ligand and Tris/TX-100 to give a final volume of 1.00 ml. When binding was examined in the presence of fatty acid or albumin in solution, these components were included in the mixture before Tris/TX-100 was added to the final volume of 1.00 ml. The concentration of radioactivity in the final mixture was 0.01-0.05 ,aCi/ml. The vials were rotated 5 min at 1800 g. Incubation for 2 h was found to be sufficient to reach equilibrium.
When 12"I-labelled ligands were used, the total radioactivity in each vial (I) and the radioactivity in 500,u of supernatant (21) were counted on a Packard Cobra Auto-Gamma instrument (Packard, Meriden, U.S.A.). The bound radioactivity (B) was determined as B = T-F. When 3H-labelled myristic acid was used, 500 ,1 of supernatant was transferred to a scintillation counting vial, 10 ml Ultima Gold (Packard) was added, and the radioactivity (12F) was counted on a Packard Tri-Carb liquid scintillation analyser. In this case, the total radioactivity in each vial was estimated from a measurement of the radioactivity (27) in 500 #1 of a mixture treated as described above but in the absence of immobilized albumin.
No unspecific binding was seen when radiolabelled acylated insulins were incubated as described above with Mini-Leak Low blocked with ethanolamine. Triton X-100 was included in the buffer to prevent non-specific binding of the acylated insulins to vials and pipettes. By varying the concentration of the detergent between 0 and 0.025% (v/v) it was found that 0.025 % (v/v) Triton X-100 prevented non-specific binding without affecting the binding to albumin. [16] .
Receptor affinity Relative affinities of l25I-(TyrAl4)-labelled insulins for the soluble insulin receptor were determined by a modification ofa previously described assay [17] . In brief, the soluble insulin receptor was immobilized on Mini-Leak to a concentration of ,uM in the gel. Various concentrations (0-20 nM) of immobilized receptor were equilibrated with 10 pM of the radiolabelled insulin in a binding buffer (pH 7.8) containing 0.1 M Hepes, 0.1 M NaCl, 0.01 M MgCl2 and 0.025 % Triton X-100 for 2 h at 23 'C. Bound tracer was isolated by centrifugation and the relative receptor affinities (RA) were calculated from a plot of bound insulin against receptor concentration as described elsewhere [17] . Human insulin represents the RA of 100%.
Animal experiments Studies in rabbits were performed on non-diabetic, fasted, male New Zealand White rabbits, 0.5-3 years of age and weighing 2.5-3.5 kg, receiving subcutaneous injections ofeither an acylated insulin or NPH-insulin. At least 1 h before dosing, the rabbits were fixed in pillories. Acylated insulins were given as aqueous at 30 rev./min for 2 h at room temperature and centrifuged for solutions containing 600 nM (100 units/ml) of insulin. The dose was 12 nmol of insulin per animal. Blood samples were drawn before and 1, 2, 4 and 6 h after injection. Glucose analysis was performed by the hexokinase method [18] .
Euglycaemic glucose clamps were carried out in non-diabetic, conscious, female pigs, cross-bred from Danish Landrace, Yorkshire and Durok, 4-5 months of age and weighing 70-95 kg. Before the experiments the pigs were fasted overnight, for 18 h. Two catheters were inserted in the jugular veins, one for glucose infusion and one for blood sampling. The pigs were free to move in their pens during the clamp period. Five pigs received NPHinsulin and LysBa9-tetradecanoyl, des-(B30) insulin in random order with an interval of 10 days. The dose was 216 nmol of insulin. The pigs were kept euglycaemic at their individual fasting glucose levels by infusion of a glucose solution (270 g/l) at a variable rate. Depending on changes in plasma glucose concentration obtained during frequent plasma glucose monitoring, the necessary adjustments of the glucose infusion were made empirically. Blood samples were collected in heparinized glass tubes every 15 min, plasma was separated, and glucose was determined within 1.5 min of blood sampling with a YSI (Yellow Springs Instruments) glucose analyser (glucose oxidase method).
RESULTS

Binding of acylated Insulins to immobilized HSA
The interaction between albumin and insulins acylated with fatty acids at the e-amino group of LysB29 was studied using albumin immobilized on agarose. This method was chosen because the size of the ligands precludes performing binding studies by dialysis. Typical plots for binding of the insulins to immobilized HSA are shown in high affinity. The capacity of albumin for binding the insulins apparently exceeds 5 mol/mol, without any indication of saturation within the tested concentration range. However, the interpretation of binding data obtained at insulin concentrations above 10 ,uM is difficult owing to extensive insulin self-association and to the relatively low solubility of the acylated insulin analogues in the applied buffer.
To quantify and compare the affinities of the fatty acid acylated insulins for HSA, '251-labelled insulins were equilibrated at 2.5 nM with various concentrations (1-20 ,uM) 
Effect profiles in vivo
The effect profiles of the fatty acid acylated insulins after subcutaneous injection into rabbits are shown in Figure 7 (a). NPH-insulin, which is the most generally used long-acting insulin suspension in the treatment of diabetes, was given as a reference. The fall in blood glucose within the first hour after injection shows that the acylated insulins have a significantly slower onset of action than NPH-insulin. Furthermore, the time until maximal effect is generally longer for the acylated insulins than for NPHinsulin. However, this time cannot be determined for all insulins, because the blood glucose was not followed beyond 6 h. As shown in Figure 7b , the initial fall in blood glucose depends on the affinity of the acylated insulin for albumin, suggesting that the protracted effect of the acylated insulins is due to albumin binding. The receptor affinity relative to human insulin for LysB29_ decanoyl insulin; LysB29-decanoyl, des-(B30) insulin; LysB29_ dodecanoyl, des-(B30) insulin; and LysB29-tetradecanoyl, des-(B30) insulin was found to be 76%, 76%, 54% and 46% respectively; the RAs for LysB29-undecanoyl, des-(B30) insulin and LysB29-tridecanoyl, des-(B30) insulin were not determined.
It has previously been shown that insulin analogues with 20-300o% receptor affinity have the same biological potency in vivo [24] . To preclude the possibility that the diminished action on blood glucose is related to a decreased bioefficacy of the acylated insulins and to study the effect profile over a longer time course, we performed a 24 h euglycaemic glucose clamp after subcutaneous injection of 216 nmol LysB29-tetradecanoyl, des-(B30) insulin and NPH-insulin into pigs. The resulting profiles are shown in Figure 8 . The cumulative glucose infusion (0-24 h) was the same after injection of LysB29-tetradecanoyl, des-(B30) insulin (2.5 + 1.3 mol) and NPH-insulin (2.6 + 0.6 mol), indicating that the two insulin preparations are equipotent in vivo. Both preparations resulted in a significant glucose consumption for at least 18 h. However, LysB29-tetradecanoyl, des-(B30) insulin showed a more protracted glucose utilization profile than NPH-insulin, the times to peak effect being 6.4 + 2.2 h and 3.4 + 0.2 h, respectively.
DISCUSSION
Derivatization of the insulin molecule with albumin-binding ligands provides a new approach to protracting the bloodglucose-lowering effect after subcutaneous injection of the hormone. Albumin is the most abundant protein in the extracellular fluid. The concentration of HSA in human plasma is about 0.6 mM [25] , whereas the level in subcutaneous interstitial fluid is about 60 % of that in plasma [12] . The protein binds a wide variety of endogenous substances and drugs with binding constants that are typically in the order of 104_106 M-1 for organic anions, and about 108 M-1 for long-chain fatty acids [7] [8] [9] [10] . We have obtained insulins with affinities of 104-105 M-1 for HSA by acylation of the e-amino group of LysB29 with saturated fatty acids containing 10 to 16 carbon atoms.
Binding mechanism
The binding of aromatic anions and fatty acids to albumin occurs by a combination of hydrophobic and ionic interactions [26] [27] [28] [29] [30] . In accord with this general mechanism, the C-terminal carboxylate group and the acyl side chain of the fatty acid acylated insulins seem to take part in the interaction with HSA. [10, 31] , respectively, whereas a large number of fatty acid anions are bound with lower affinity [22, 32] . [3] . At present, a neutral solution of human insulin provides the rapid-acting component, whereas a prolonged action is obtained by injection of insulin suspensions of crystals with protamine or zinc. It has recently been convincingly shown that the onset of diabetic late complications can be delayed by intensive treatment with insulin [35] . To permit a tighter control of the blood glucose, it is desirable to insulin [36] and long-acting insulins with a smoother and more reproducible effect profile than the insulin suspensions [37] . The acylated insulins provide a breakthrough in the search for soluble, prolonged-action insulins for basal delivery of the hormone to diabetic patients. The mechanism of protraction is probably binding to albumin in the subcutaneous tissue, resulting in a lower absorption rate of the acylated insulins than of human insulin. Binding to albumin in plasma may increase the plasma half-life of the acylated insulins relative to that of human insulin and contribute to prolong the action profiles. The selection of a specific insulin derivative for drug development based on studies in a pig model will be discussed elsewhere.
As the acylated insulins compete with fatty acids for binding to human albumin, the plasma level of free fatty acids may influence the effect profile of the acylated insulins. In normal subjects, the molar ratio of free fatty acids to albumin varies between 0.5 and 1.0, depending on the nutritional state [38] . Provided that albumin is present in large excess over insulin, which is the case in vivo, the binding of acylated insulins is only affected to a minor degree by fluctuations in the free fatty acid level within this range. A transient high level of free fatty acids is expected to have a minor effect on the rate by which insulin is released into the bloodstream, because the absorption of unbound insulin occurs relatively slowly, i.e. with a half-time of 1-2 h [36] .
Derivatization with albumin-binding ligands as described here may provide a general approach to prolonging the effect of peptide drugs. Owing to the linkage between binding affinity and degree of protraction, the action profile can be engineered by modification of the ligand structure. The knowledge of the crystal structure of human serum albumin and the possibility of performing X-ray analysis of albumin bound with ligands such as fatty acids [10, 26] are likely to prove useful in the future design of peptide derivatives with an affinity for specific albuminbinding sites.
